Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions accepted

The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.

Submissions

735 documents · page 1 of 25

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-CERTAINTY-FR/001Draft revision of the Institute’s certainty assessment framework…Dr Anselm Thorsby-NakamuraQuantitative claims are reproduced without the method that produced them
DRAFT-CERTAINTY-FR/002Draft revision of the Institute’s certainty assessment framework…Dr Adaeze Underhill-OkaforThe framework should say when a rating must not be issued at all
DRAFT-CERTAINTY-FR/007Draft revision of the Institute’s certainty assessment framework…Dr Vasilisa ImmelmannIt is not clear which provisions bind the assessment committee
DRAFT-CERTAINTY-FR/009Draft revision of the Institute’s certainty assessment framework…Dr Yusuf Whitmarsh-ObiNothing states how many assessors rate a body of evidence
DRAFT-CERTAINTY-FR/010Draft revision of the Institute’s certainty assessment framework…Dr Vittoria QuintanilhaNothing prevents a conclusion stronger than its certainty rating
DRAFT-CERTAINTY-FR/011Draft revision of the Institute’s certainty assessment framework…Dr Jozef Brandvold-AchterbergThe framework does not say what new evidence would change a rating
DRAFT-CERTAINTY-FR/012Draft revision of the Institute’s certainty assessment framework…Dr Ottoline Oppenheimer-AdeA composite outcome is rated as one outcome
DRAFT-CERTAINTY-FR/014Draft revision of the Institute’s certainty assessment framework…Thaddeus Isaksen-BalogunThe treatment of imprecision does not work where the event did not occur
DRAFT-SUPPLIER-RUB/001Draft supplier evaluation rubricDr Vasilisa ImmelmannTwo criteria can be satisfied without changing anything a supplier does
DRAFT-SUPPLIER-RUB/005Draft supplier evaluation rubricDr Eamon ImmelmannWhether a purchaser can obtain the record behind a figure is not scored
DRAFT-SUPPLIER-RUB/006Draft supplier evaluation rubricStellan Cholmondeley-AdeScores from different rubric versions are presented together
DRAFT-SUPPLIER-RUB/008Draft supplier evaluation rubricDr Zebedee Zaleski-MbekiAn accreditation claim is scored without being verified
DRAFT-SUPPLIER-RUB/010Draft supplier evaluation rubricDr Frideswide NordhagenA high score invites a purchasing decision the rubric cannot support
DRAFT-COA-MINIMUM-/002Draft certificate-of-analysis minimum data standardProfessor Bartolomeu Nkosi-LindegaardA conformance claim is not defined and will be made loosely
DRAFT-COA-MINIMUM-/004Draft certificate-of-analysis minimum data standardDr Yusuf Whitmarsh-ObiAbsence of evidence is presented in a form a reader will take as negative evidence
DRAFT-COA-MINIMUM-/005Draft certificate-of-analysis minimum data standardDr Quentin ZimmerthalThe draft prescribes a procedure where it should state performance
DRAFT-COA-MINIMUM-/007Draft certificate-of-analysis minimum data standardDr Anselm Thorsby-NakamuraQuantitative claims are reproduced without the method that produced them
DRAFT-COA-MINIMUM-/008Draft certificate-of-analysis minimum data standardDr Fitzwilliam Danquah-ÖbergThe scope does not say which materials the standard excludes
DRAFT-COA-MINIMUM-/009Draft certificate-of-analysis minimum data standardEamon Sandringham-AduA determination does not record the version of the standard it was made under
DRAFT-RP-HPLC-PURI/001Draft standard: determination of chromatographic purity by…Dr Liesbeth Nyquist-ObioraThe standard does not state that a determination on one unit says nothing about the batch
DRAFT-RP-HPLC-PURI/002Draft standard: determination of chromatographic purity by…Rukayat Zaleski-MbekiThe matrix interferes with the determination and no control is required
DRAFT-SEMAGLUTIDE-/001Draft monograph: semaglutide, version 3Dr Sigrún VercingetorixA near-isobaric analogue is not distinguished by the identity determination described
DRAFT-SEMAGLUTIDE-/002Draft monograph: semaglutide, version 3Dr Lorcan Zaleski-MbekiLocal reactions are omitted from the adverse-event table because the trials reported them separately
DRAFT-SEMAGLUTIDE-/003Draft monograph: semaglutide, version 3Dr Fenella LavrentievGlycaemic trials and weight-management trials are drawn on interchangeably
DRAFT-SEMAGLUTIDE-/005Draft monograph: semaglutide, version 3Dr Delphine TrelawneyThe pharmacokinetic section does not connect half-life to the dosing schedule
DRAFT-SEMAGLUTIDE-/006Draft monograph: semaglutide, version 3Dr Quentin ZimmerthalQuantitative claims are reproduced without the method that produced them
DRAFT-SEMAGLUTIDE-/010Draft monograph: semaglutide, version 3Dr Yehudit YorkstoneMechanistic claims for a peptide fragment are carried without evidence that the fragment acts as…
DRAFT-SEMAGLUTIDE-/011Draft monograph: semaglutide, version 3Dr Yusuf Whitmarsh-ObiEvery contributing trial shares one sponsor and the monograph does not say so
DRAFT-SEMAGLUTIDE-/013Draft monograph: semaglutide, version 3Dr Vittoria QuintanilhaRegistered trials that never reported are absent from the monograph
DRAFT-SEMAGLUTIDE-/014Draft monograph: semaglutide, version 3Dr Marisol Dunmore-EkpoOpen-label extension data are presented alongside randomised data without distinction

page 1 of 25

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.